Regeneus CEO John Martin Talks About the Licensing of Progenza in Japan
Regeneus Ltd (ASX:RGS) is an Australian clinical-stage regenerative medicine company developing a portfolio of innovative cellular therapies targeting significant unmet medical needs in both human and animal health markets.
With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.
The Japanese deal means the company is moving quickly into a new stage of growth as explained by CEO John Martin in a video interview.
Read the full article by ABN Newswire via BioSpace here.
Regeneus reports first half-year profit, funded for eighteen months
Regeneus (ASX:RGS) reported a $3.8 million profit in the first half of FY17 after coming off a $3.1 million loss in FY16.
The profit improvement was driven by the receipt of an upfront licence fee from AGC of Japan (TYO:5201) valued at US$5.5 million, which supports an 18 month funding runway.
Read the full article by Proactive Investors here.
Regeneus Hits the Fast Track with Major Japanese Partnership
Regeneus, an Australian regenerative medicine company, has entered into an collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future.
Read the full article by The Life Sciences Report here.
Companies Flocking to Japan for Biotech Deals: CJ Partners' Colin Lee Novick
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. For The Life Sciences Report Tokyo-based Colin Lee Novick, Managing Director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead.
View the full transcript via The Life Sciences Report here.
Regeneus receives cash payment from Japan partner
The strategic collaboration and licensing agreement recently entered into is for the manufacture, clinical development and commercialisation of Progenza in Japan.
Progenza is a patented off-the-shelf stem cell technology developed for the treatment of knee osteoarthritis and other inflammatory conditions.
Read the full article by Proactive Investors here.
Regeneus enters 2017 backed by transformational Japan deal
Regeneus (ASX:RGS) has a busy 2017 to come, spearheaded by its recent entry into the Japanese market for its Progenza product.
The company entered into a strategic collaboration and licensing agreement for the manufacture, clinical development and commercialisation of Progenza in Japan.
Read the full article by Proactive Investors here.
Regeneus Q4 2016 News Update
Regeneus released our Q4 2016 update newsletter designed to keep our investors and followers of the company up to date with all the company and industry news over the last quarter.
Read our Q4 2017 newsletter here.